Allergy hosts Satellite Symposium at EAACI

RNS Number : 9430A

Allergy Therapeutics PLC

13 June 2016

 

 

13 June 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Allergy Therapeutics hosts Satellite Symposium at EAACI

~ World-leading allergists present technological advances and immunotherapy innovations ~

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces today that data was presented in a Satellite Symposium entitled: "Adjuvants in Allergy: elevating efficacy" at the 35^th Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Vienna, Austria on 12 June 2016, relating to a number of the Company's products and technologies.

Three world-leading experts in the field of allergen immunotherapy and vaccine delivery, Ralph Mösges, Randolph Brehler and Thomas Kündig, presented information on innovation in immunotherapy including Allergy Therapeutics' key product Pollinex Quattro®. Pollinex Quattro®'s specialist technology was discussed, highlighting the marketed product's ability to reduce irritation and systemic reactions.  Furthermore, Dr Brehler discussed how the potent depot adjuvant MCT (Micro Crystalline Tyrosine), initiated by the Company as an alternative to aluminium in subcutaneous immunotherapy and used in Pollinex Quattro® as well as certain other of the Company's subcutaneous injected therapies, has an immunomodulating action that augments a shift in the immune reactions responsible for the symptoms of allergic rhinitis.

Data on the future role of Virus-Like-Particles (VLP) in immunotherapy was also presented as a potential new injectable vaccine immunotherapy technology. Allergy Therapeutics recently acquired an exclusive VLP technology licence and is conducting a research project on VLP-based allergy vaccines. The worldwide food allergy market is worth a potential $8bn and, currently, there is no established and safe immunotherapy treatments available for peanut allergy, the first indication the Company intends to address.

Manuel Llobet, Chief Executive Officer, commented: "As a fully integrated specialty pharmaceutical company, we are delighted to be breaking new ground in allergen immunotherapy. Allergy Therapeutics has the potential to transform allergy treatment with an established range of diagnostics and specific short-course aluminium-free immunotherapy vaccines and we are well-placed to deliver the relief from symptoms of allergy that millions of patients need." 

Satellite Symposium: Adjuvants in Allergy: elevating efficacy

1)   Ultra-short course immunotherapy, Ralph Mösges MD, PhD, MSEE, University of Cologne (Pulmonology, Allergology and Clinical Immunology)

2)   Adjuvants in immunotherapy, Randolf Brehler MD, University of Münster (Allergology)

3)   Future immunotherapy: virus like particles, Thomas Kündig, University Hospital Zurich (Immunology, Cell Biology and Pharmacology) 

ENDS

For further information please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY).

For more information please see www.allergytherapeutics.com.

 

END

 

 

NRAAKBDBBBKBDAD